Krystal Biotech, Inc. (KRYS) 의 후행 P/E는 36.4, 선행 P/E 35.3. 후행 이익수익률은 2.75%, 선행 이익수익률 2.83%. PEG 0.28 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $81.91.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 85/100 4/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | -39.6 | 0.00 | 157.41 | 0.00 | - |
| 2017 | -7.1 | -0.02 | 1.14 | 0.00 | - |
| 2018 | -21.4 | 0.62 | 2.06 | 226.68 | - |
| 2019 | -46.1 | -1.95 | 4.34 | 0.00 | - |
| 2020 | -35.0 | -0.82 | 3.86 | 0.00 | - |
| 2021 | -22.3 | -0.27 | 2.62 | 0.00 | - |
| 2022 | -14.4 | -0.19 | 3.87 | 0.00 | - |
| 2023 | 308.2 | -2.87 | 4.33 | 66.45 | - |
| 2024 | 50.2 | 0.07 | 4.73 | 15.42 | - |
| 2025 | 34.8 | 0.27 | 5.85 | 18.34 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $-0.27 | $0.00 | $-1.15M | - |
| 2017 | $-1.48 | $0.00 | $-7.92M | - |
| 2018 | $-0.97 | $1.03M | $-10.89M | -1060.3% |
| 2019 | $-1.20 | $0.00 | $-19.09M | - |
| 2020 | $-1.71 | $0.00 | $-32.17M | - |
| 2021 | $-3.13 | $0.00 | $-69.57M | - |
| 2022 | $-5.49 | $0.00 | $-139.98M | - |
| 2023 | $0.39 | $50.7M | $10.93M | 21.6% |
| 2024 | $3.00 | $290.52M | $89.16M | 30.7% |
| 2025 | $6.84 | $389.13M | $204.83M | 52.6% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $7.64 | $5.57 – $9.24 | $524.35M | $472.59M – $575.72M | 8 |
| 2027 | $9.95 | $5.03 – $15.36 | $671.48M | $574.67M – $768.29M | 7 |
| 2028 | $13.46 | $8.34 – $27.13 | $899.45M | $872.5M – $926.41M | 5 |
| 2029 | $20.30 | $15.80 – $26.05 | $1.15B | $951.31M – $1.4B | 1 |
| 2030 | $27.11 | $21.11 – $34.80 | $1.45B | $1.2B – $1.77B | 1 |
